How to buy ANI Pharmaceuticals stock

ANI Pharmaceuticals, Inc is a drug manufacturers-specialty & generic business based in the US. ANI Pharmaceuticals shares (ANIP) are listed on the NASDAQ and all prices are listed in US Dollars. ANI Pharmaceuticals employs 369 staff and has a trailing 12-month revenue of around 0.00.

ANI Pharmaceuticals share price

Use our graph to track the performance of ANIP stocks over time.

ANI Pharmaceuticals shares at a glance

• Key figures

Information last updated 2021-04-30.

52-week range	$23.55 - $40.78
50-day moving average	$33.10
200-day moving average	$30.45
Wall St. target price	$38.33
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$1.34

Buy ANI Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy ANI Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of ANI Pharmaceuticals, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is ANI Pharmaceuticals under- or over-valued?

Valuing ANI Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of ANI Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

ANI Pharmaceuticals's PEG ratio

ANI Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.06. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into ANI Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

ANI Pharmaceuticals's EBITDA

ANI Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $39.9 million.

The EBITDA is a measure of a ANI Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

ANI Pharmaceuticals financials

Revenue TTM	$208.5 million
Gross profit TTM	$125.6 million
Return on assets TTM	-0.65%
Return on equity TTM	-11.04%
Profit margin	-10.82%
Book value	$16.31
Market capitalisation	$411.5 million

TTM: trailing 12 months

Shorting ANI Pharmaceuticals shares

There are currently 527,264 ANI Pharmaceuticals shares held short by investors – that's known as ANI Pharmaceuticals's "short interest". This figure is 3% up from 511,683 last month.

There are a few different ways that this level of interest in shorting ANI Pharmaceuticals shares can be evaluated.

ANI Pharmaceuticals's "short interest ratio" (SIR)

ANI Pharmaceuticals's "short interest ratio" (SIR) is the quantity of ANI Pharmaceuticals shares currently shorted divided by the average quantity of ANI Pharmaceuticals shares traded daily (recently around 65580.099502488). ANI Pharmaceuticals's SIR currently stands at 8.04. In other words for every 100,000 ANI Pharmaceuticals shares traded daily on the market, roughly 8040 shares are currently held short.

However ANI Pharmaceuticals's short interest can also be evaluated against the total number of ANI Pharmaceuticals shares, or, against the total number of tradable ANI Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ANI Pharmaceuticals's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 ANI Pharmaceuticals shares in existence, roughly 40 shares are currently held short) or 0.0654% of the tradable shares (for every 100,000 tradable ANI Pharmaceuticals shares, roughly 65 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against ANI Pharmaceuticals.

Find out more about how you can short ANI Pharmaceuticals stock.

ANI Pharmaceuticals share dividends

We're not expecting ANI Pharmaceuticals to pay a dividend over the next 12 months.

Have ANI Pharmaceuticals's shares ever split?

ANI Pharmaceuticals's shares were split on a 1:6 basis on 17 July 2013. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your ANI Pharmaceuticals shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for ANI Pharmaceuticals shares which in turn could have impacted ANI Pharmaceuticals's share price.

ANI Pharmaceuticals share price volatility

Over the last 12 months, ANI Pharmaceuticals's shares have ranged in value from as little as $23.55 up to $40.7755. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ANI Pharmaceuticals's is 1.3116. This would suggest that ANI Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

ANI Pharmaceuticals overview

ANI Pharmaceuticals, Inc. , a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract manufacturing for other pharmaceutical companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was founded in 2001 and is headquartered in Baudette, Minnesota. .

Frequently asked questions

• What percentage of ANI Pharmaceuticals is owned by insiders or institutions?

  Currently 5.715% of ANI Pharmaceuticals shares are held by insiders and 80.777% by institutions.

• How many people work for ANI Pharmaceuticals?

  Latest data suggests 369 work at ANI Pharmaceuticals.

• When does the fiscal year end for ANI Pharmaceuticals?

  ANI Pharmaceuticals's fiscal year ends in December.

• Where is ANI Pharmaceuticals based?

  ANI Pharmaceuticals's address is: 210 Main Street West, Baudette, MN, United States, 56623

• What is ANI Pharmaceuticals's ISIN number?

  ANI Pharmaceuticals's international securities identification number is: US00182C1036

• What is ANI Pharmaceuticals's CUSIP number?

  ANI Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 00182C103